Doing so in larger cohorts of CML patients would lead to very pinpointed cytogenetic diagnosis from CP to AP and impact a patient's prognosis and subsequent treatment, since therapeutic possibilities targeting the BCR-ABL translocation are constantly growing [40]. Here, BCR is linked to chronic myelogenous leukemia, BCR-ABL1 positive.